Prof. Dr. Frank Dörje

Naturwissenschaftliche Fakultät Lehrstuhl für Pharmazeutische Technologie und Biopharmazie Apotheke des Universitätsklinikums Professur für Molekulare und Klinische Pharmazie

Möglichkeiten der Fertigung von Testallergenen in öffentlichen Apotheken zur Diagnostik von Typ I-Allergien – rechtliche Aspekte (2024) Jost R, Kespohl S, Paulus-Tremel KE, Zimmer J, Bonertz A, Sander I, Klose T, et al. Journal article, Review article Ein Fall für Interprofessionalität – Perioperatives Management von Sorafenib (2024) Lensker P, Busse M, Dörje F Journal article A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center. (2024) Cuba L, Dürr P, Geßner K, Häcker B, Fietkau R, Siebler J, Pavel ME, et al. Journal article From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy (2024) Cuba L, Dürr P, Dörje F, Fromm M, Schlichtig K Journal article Sobetirome rescues α-synuclein-mediated demyelination in an in vitro model of multiple system atrophy (2023) Meszaros L, Himmler M, Schneider Y, Arnold P, Dörje F, Schubert DW, Winkler J Journal article Promotionspreis für Krankenhauspharmazie (2023) Dörje F Journal article Optimizing Medication Safety with Oral Antitumor Therapy: A Methodological Approach for the Real-World Implementation of the AMBORA Competence and Consultation Center (2023) Cuba L, Schlichtig K, Dürr P, Inwald EC, Fromm M, Dörje F Journal article Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial (2022) Dürr P, Meier F, Schlichtig K, Schramm A, Schötz L, Fromm M, Dörje F Journal article Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial (2022) Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Journal article